NanoViricides (NNVC) AI Stock Analysis

• Market Cap: $22.46M
• Dividend Yield: N/A
• Average Volume (3M): 143.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: 32.92%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 21,595,000
• 10 Day Avg. Volume: 199,739
• 30 Day Avg. Volume: 143,335
• PEG Ratio: 0.22
• Price to Book (P/B): 2.82
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.48
• Enterprise Value/Market Cap: -229.33K
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 15.88M
• Enterprise Value/Ebitda: 667.80K
• 1Y Price Target: $6.00
• Price Target Upside: 430.97% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $0.99 ▼(-12.48% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is primarily constrained by financial performance: no revenue, persistent losses, and ongoing cash burn that implies continued funding/dilution risk. Technicals add downside pressure with the stock trading below key longer-term moving averages and negative MACD. Valuation provides limited support due to negative earnings and no stated dividend yield.

Positive Factors

Proprietary broad‑spectrum nanoviricide platform

NanoViricides’ proprietary nanoviricide platform is a structural competitive asset: a mechanism designed to bind and neutralize viruses that can be applied across multiple viral indications. A reusable platform increases R&D optionality, supports pipeline breadth, and makes partnerships or licensing more likely over the medium term.

Very low financial leverage

Near‑zero debt materially reduces solvency and interest‑service risk, preserving strategic flexibility to pursue development, licensing, or staged financing. This structural low‑leverage profile makes the company less vulnerable to rising rates or covenant stress and supports longer runway management decisions.

Regulatory pathway progress: orphan filings for NV‑387

Orphan designation filings for NV‑387 signal a potential regulatory and commercial pathway for niche indications. Orphan status can provide fee waivers, regulatory support, and market exclusivity benefits, improving the long‑term development economics and attractiveness to partners or acquirers.

Negative Factors

Pre‑revenue with persistent net losses

Being pre‑revenue and consistently loss‑making is a core structural weakness: there is no commercial cash flow to fund operations or validate the technology. The company remains dependent on external financing to advance trials, increasing execution risk and making long‑term sustainability contingent on successful approvals or partnerships.

Consistent negative operating and free cash flow

Persistent operating and free cash‑flow outflows that align with net losses indicate real cash burn rather than non‑cash charges. The absence of a discernible improvement trend raises the likelihood of near‑term financing rounds, heightening dilution risk and potentially distracting management from long‑term execution priorities.

Material decline in shareholders' equity

A marked decline in shareholders’ equity reflects cumulative losses and prior financings, shrinking the capital buffer available for R&D and increasing reliance on external capital. This erosion heightens dilution risk, reduces financial resilience, and constrains strategic choices for advancing late‑stage development without partner funding.

NanoViricides Business Overview & Revenue Model

Company Description

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

How the Company Makes Money

NanoViricides makes money primarily through the development and commercialization of its proprietary antiviral drug candidates. As the company is primarily in the research and development phase, its current revenue streams are limited to potential grants, research collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships can provide funding and resources in exchange for rights to develop or market NanoViricides' technologies. Additionally, the company may earn revenue in the future through product sales once its drugs receive regulatory approval and are launched in the market. Until then, its financial health is heavily reliant on investment funding and strategic partnerships to support its ongoing research activities.

NanoViricides Financial Statement Overview

Summary

Income statement is very weak with no revenue and persistent, sizable losses. Cash flow shows ongoing operating and free-cash-flow burn with no clear improvement, implying continued funding needs. Balance sheet is a partial offset with near-zero leverage, but equity has declined materially over time, increasing dilution/runway risk.

Income Statement

NNVC reports no revenue across the annual periods provided, which leaves the business fully dependent on funding rather than commercial execution. Losses are persistent and sizable, with net losses staying deeply negative each year (and extremely large in the latest TTM (Trailing-Twelve-Months) dataset), indicating weak operating leverage and limited visibility to near-term profitability. A modest positive is that annual losses have not accelerated dramatically from 2022–2025, but overall earnings quality remains very weak given the lack of revenue and ongoing operating losses.

Balance Sheet

The balance sheet shows essentially no leverage (debt is near-zero and debt-to-equity is minimal), which reduces solvency risk and provides flexibility. However, equity has trended down meaningfully over time (from about $29.9M in 2021 to about $7.5M in 2025 annual), reflecting cumulative losses and potential dilution risk. Returns on equity are consistently negative, highlighting that the capital base is not generating profits.

Cash Flow

Cash generation is consistently negative, with operating cash flow and free cash flow both outflows each year, implying ongoing cash burn. Free cash flow is roughly in line with net losses (free cash flow to net income is near 1.0), which suggests reported losses broadly translate into real cash usage rather than being purely non-cash. A key weakness is the lack of evidence of improving cash burn trajectory in the annual data (free cash flow growth is mixed and often negative), raising ongoing funding needs.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-324.27K	0.00	0.00	-747.53K	0.00	0.00
EBITDA	-7.71M	-8.72M	-7.49M	-7.84M	-7.38M	-8.04M
Net Income	-8.32M	-9.47M	-8.29M	-8.59M	-8.11M	-8.82M
Balance Sheet
Total Assets	12.27T	8.82M	12.82M	16.90M	23.49M	30.26M
Cash, Cash Equivalents and Short-Term Investments	5.15T	1.56M	4.80M	8.15M	14.07M	20.52M
Total Debt	0.00	0.00	0.00	0.00	94.79K	95.31K
Total Liabilities	1.20T	1.31M	1.36M	2.03M	412.84K	351.15K
Stockholders Equity	11.07T	7.52M	11.46M	14.87M	23.08M	29.91M
Cash Flow
Free Cash Flow	-3.73T	-8.54M	-6.47M	-5.82M	-6.22M	-8.45M
Operating Cash Flow	-3.64T	-8.48M	-6.32M	-5.67M	-5.89M	-8.21M
Investing Cash Flow	-94.52K	-56.96K	-156.56K	-151.71K	-324.35K	-238.76K
Financing Cash Flow	8.62M	5.30M	3.12M	-94.79K	-234.72K	15.26M

NanoViricides Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NNVC, the sentiment is Neutral. The current price of 1.13 is above the 20-day moving average (MA) of 0.99, above the 50-day MA of 1.11, and below the 200-day MA of 1.38, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 50.25 is Neutral, neither overbought nor oversold. The STOCH value of 69.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NNVC.

NanoViricides Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SABS	50 Neutral	$178.05M	-1.21	-21.16%	―	-92.42%	62.37%
ENLV	49 Neutral	$272.99M	-2.15	-57.64%	―	―	46.09%
CASI	46 Neutral	$12.39M	-0.25	―	―	26.20%	-42.26%
MBRX	45 Neutral	$7.54M	-0.04	―	―	―	79.31%
NNVC	42 Neutral	$22.46M	-2.16	-94.03%	―	―	32.92%
AKTX	42 Neutral	$8.32M	―	-196.60%	―	―	―

NanoViricides Corporate Events

NanoViricides Holds 2025 Annual Stockholders Meeting

On November 22, 2025, NanoViricides, Inc. held its 2025 Annual Meeting of Stockholders, where approximately 61% of the company’s voting capital stock was represented. The shareholders approved the re-election of Anil Diwan as a Class I Director, an advisory vote on executive compensation, and the ratification of EisnerAmper, LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026. These decisions reflect the company’s ongoing commitment to its leadership and financial oversight, potentially impacting its operational stability and investor confidence.